| Dr Matthew Charles Brouns, MD | |
|
210 Se 136th Ave, Vancouver, WA 98684-6930 | |
| (360) 944-9889 | |
| (360) 944-9686 |
| Full Name | Dr Matthew Charles Brouns |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 210 Se 136th Ave, Vancouver, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508869546 | NPI | - | NPPES |
| 1012066 | Medicaid | WA | |
| 139471 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD00037209 (Washington) | Primary |
| Entity Name | Northwest Cancer Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407828114 PECOS PAC ID: 8426943838 Enrollment ID: O20040216000873 |
News Archive
Researchers at the University of Twente, in cooperation with commercial parties, are developing a portable device for detecting type 1 or type 2 diabetes at an early stage.
Women who received a text message reminding them about their breast cancer screening appointment were 20 per cent more likely to attend than those who were not texted, according to a study published in the British Journal of Cancer today (Thursday).
BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).
The cancer caused by this new cancer gene is called adenoid cystic carcinoma and is a slow-growing but deadly form of cancer. The research group can now show that the gene is found in 100% of these tumours, which means that a genetic test can easily be used to make a correct diagnosis.
Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Charles Brouns, MD 210 Se 136th Ave, Vancouver, WA 98684-6930 Ph: (360) 944-9889 | Dr Matthew Charles Brouns, MD 210 Se 136th Ave, Vancouver, WA 98684-6930 Ph: (360) 944-9889 |
News Archive
Researchers at the University of Twente, in cooperation with commercial parties, are developing a portable device for detecting type 1 or type 2 diabetes at an early stage.
Women who received a text message reminding them about their breast cancer screening appointment were 20 per cent more likely to attend than those who were not texted, according to a study published in the British Journal of Cancer today (Thursday).
BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).
The cancer caused by this new cancer gene is called adenoid cystic carcinoma and is a slow-growing but deadly form of cancer. The research group can now show that the gene is found in 100% of these tumours, which means that a genetic test can easily be used to make a correct diagnosis.
Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.
› Verified 6 days ago
Kanuboddu Nagarjuna Reddy, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave Ste 220, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. David Steiger, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 505 Ne 87th Ave Ste 301, Vancouver, WA 98664 Phone: 360-514-7374 Fax: 360-514-7384 | |
Phillip M Cullison Bonner, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1000 | |
Louise M Schultz, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-882-2778 | |
Marissa Krienke, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 700 Ne 87th Ave Ste And240, Vancouver, WA 98664 Phone: 360-882-2778 | |
Joel David Mclarry, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Suite 210, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. Samuel Everett George, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19005 Se 34th St Bldg 3, Vancouver, WA 98683 Phone: 360-726-6720 Fax: 360-726-6729 |